News and Trends 19 Sep 2022
FDA boosts Antengene pancreatic cancer treatment
Biopharma company Antengene Corporation Limited says ATG-101, the company’s in-house developed novel PD-L1/4-1BB bispecific antibody, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. The company said the ODD will help Antengene facilitate regulatory communication with the FDA, accelerate the clinical development […]
